**2**015

APR 2 0 2005

Group Art Unit No.: 1644

Via Facsimile - (703) 872-9306 MAIL STOP AMENDMENT

PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Peter R. Baum and William C. Fanslow, III Applicants:

Serial No.: 10/622,237 Examiner: M. Haddad July 17, 2003 Filed:

ANTIBODIES THAT BIND LDCAM (AS AMENDED) For:

Docket No.: 2873-USA

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/778,187 filed February 6, 2001. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complles with 37 CFR 1.98(a)-(c).

The above-cited list is submitted under § 1.97(c) and accompanied by the fee of \$180 as set forth in § 1.17(p). The Commissioner is authorized to charge the \$180 fee and any other fees which may be required to Deposit Account No. 09-0089. A duplicate copy of this sheet is enclosed.

Applicants request consideration of this information and passage of the application to issue.

Immunex Corporation Law Department 1201 Amgen Court West Seattle, WA 98119-3105 (206) 265-7000

Respectfully submitted,

James E. Klaniecki

Attorney/Agent for Applicants

Registration No.: 38,207 Phone: (206) 265-7145

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below.

Date: April 20, 2005

**2**018

APR 2 0 2005

Via Facsimile - (703) 872-9306 MAIL STOP AMENDMENT PATENT APPLICATION

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter R. Baum and William C. Fanslow, III

Serial No.: 10/622,237

Group Art Unit No.: 1644

Filed:

July 17, 2003

Examiner: M. Haddad

For:

ANTIBODIES THAT BIND LDCAM (AS AMENDED)

Docket No.: 2873-USA

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/778,187 filed February 6, 2001. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).

The above-cited list is submitted under § 1.97(c) and accompanied by the fee of \$180 as set forth in § 1.17(p). The Commissioner is authorized to charge the \$180 fee and any other fees which may be required to Deposit Account No. 09-0089. A duplicate copy of this sheet is enclosed.

Applicants request consideration of this information and passage of the application to issue.

Immunex Corporation Law Department 1201 Amgen Court West Seattle, WA 98119-3105 (206) 265-7000 Respectfully submitted,

James E. Klaniecki

Attorney/Agent for Applicants Registration No.: 38,207

Phone: (206) 265-7145

#### CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below.

Signed Mand M Kertson

Date: April 20, 2005

1

PAGE 16/18 \* RCVD AT 4/20/2005 7:58:23 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-1/0 \* DNIS:8729306 \* CSID:206 233 0644 \* DURATION (mm-ss):04-32

BEST AVAILABLE COP

VIA Facsimile - (703) 872-9306 Mail Stop Amendment

		PATE	ARTMENT OF COUT AND TRADE	MARX OFFICE	ATTORNEY DOCKET NO. 2873-USA		10/62:	2,237				
(		SCLOS	IRE CITA				10/622,237					
	Use severa		INFORMATION DISCLOSURE CITATION					Peter R. Baum and William C. Fanslow III				
	Use severa						FILING DATE GROUP					
XAMINER		l sheets if r		July 17, 2003 1644								
KAMINER				I.S. PATENT	DOCUMENTS		<del> </del>					
	DOCUME	UMENT NUMBER DATE NAME		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
A1	0,312,0	95	01.28.03	Baum		 						
A2	US-200	2/0198147	12.2002	Baker et al.		<del> </del>						
A3	6,642,	6,642,360 11.2003 Filvaroff et al.		<u> </u>	l							
····			FO	REIGN PATI	ENT DOCUMENTS			Γ				
	DOCUME	NT NUMBER	DATE		COUNTRY			TRANSL YES	HOITAJENART NO			
B	wo99	/28462	06/10/99	PCT					ļ <del>-</del>			
B2	2 WO99	7/57132	11/11/99	РСТ		<u> </u>	<del> </del>	-				
В	3 WO00	)/29435	05/25/00	PCT		ļ	<del> </del>	<del>                                     </del>	_			
В	4 WOO	0/32776	06/08/00	PCT		-		<del> </del>	-			
В	5 WO0	1/00237A1	01/04/01	PCT		<del> </del>		┼	-			
В	6 W00	1/54477A2	08/02/01	PCT		┼─	<del> </del>	-	$\vdash$			
В		2/26930A2	04/04/02	PCT		<u> </u>		<u> </u>	<u>l_</u>			
					thor, Title, Date, Pertine		Etc.)	<del></del>				
	1 Attwee	ood, T. "Th	e bable of b	noinformatio	os," Science, 290:47-49, 2000.							
	prote	Bost, K.L. and Pascual, D.W., "Antibodies against a peptide sequence within the HIV envelope protein crossreacts with human interleukin-2," <i>Immunol. Invest.</i> , 17(6-7):577-586, 1988.										
	gene	Gomyo, H. et al., "A 2-Mb sequence-ready contig map and a novel immunoglobulin superfamily gene IGSF4 in the LOH region of chromosome 11q23.2," Genomics, 62:139-146, 1999.										
- (	24	Greene, J.L. et al., "Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cells costimulatory interactions," J. Biol. Chem., 271(6):26762-26771, 1996.										
	75 Line	Linsley P.S. et al., "Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4										
<del> </del>	- (CI	(CTLA-4)," J. Biol. Chem., 270(25):15417-15424, 1995.  Metzler et al., "Solution structure of human CLTA-4 and delineation of a CD80/CD86 binding si										
	cons	conserved in CD28," Nature Structural Biol., 4:527-531, 1997.										
	appr	Skolnick et al. "From genes to protein structure and function: novel applications of computation approaches in the genomic era," <i>Trends in Biotech.</i> , 18(1):34-39, 2000.										
	C8 Stra	Strausberg, R., Genebank, Accession No. AA493561, August 28, 1997.										
EXAMINER												

VIA Facsimile - (703) 872-9306 Mail Stop Amendment

Sheet 2 of \_\_2

		40 U.S. DEPARTMENT OF COMMERCE	ATTORNEY DOCKET NO.	SERIAL NO.				
Form PT	O-14	PATENT AND TRADEMARK	2873-USA	10/622,237				
INFO	RMA	TION DISCLOSURE CITATION	Peter R. Baum and William C. Fanslow III					
•••			PELING DATE GROUP					
			July 17, 2003	1644				
·		(Supplemental Sheet)						
		OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent Page	s, Etc.)				
	C9	The RIKEN Genome Exploration Research "Functional annotation of a full-length mo	ouse cDNA collection," Natura	g 409:063-090, 2001				
	C10	Urase K., et al., Expression of TRA175 mRNA, a new member of the immunoglobulin superfamily, in developing mouse brain," <i>NeuroReport</i> 12(15):3217-3221, Oct. 2001						
	C11	Wakayama T., et al., "Cloning and Characterization of a Novel Mouse Immunoglobulin Superfamily Gene Expressed in Early Spermatogenic Cells," Molecular Reproduction and Development 60:158-164, 2001						
				_				
	ļ							
		·						
				<del></del>				
	<u> </u>							
	_							
EXAMINE			DATE CONSIDERED					
*EXAMIN	IER: ir	nitial if citation considered, whether or not citatic ence and not considered. Include copy of this	on is in conformance with MPEP to form with next communication to	309; Draw line through citation if applicant.				

PAGE 18/18 \* RCVD AT 4/20/2005 7:58:23 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-1/0 \* DNIS:8729306 \* CSID:206 233 0644 \* DURATION (mm-ss):04-32